Before you sell to, join or invest in Imunon, Inc.
MentionFox check on Imunon, Inc.: only 2 sources on file so far (checked 4 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/imunon-inc-form-d-25000001
Check Imunon, Inc. before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.
What do you want to do about Imunon, Inc.?
Based on the records MentionFox holds for this company. No flag is not a clearance.
Imunon, Inc. filed a Form D with the Securities and Exchange Commission on 2025-05-28.
Imunon, Inc. filed a Form D notice of an exempt securities offering with the SEC on May 28, 2025. The filing reports $3.25M sold. Its industry group is Biotechnology. It names Stacy Lindborg (President and Chief Executive Officer), Michael Tardugno (Executive Chairman), David Gaiero (Chief Financial Officer) (SEC Form D, May 28, 2025).
Is this your company?
Sell to companies like Imunon, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-05-28 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Imunon, Inc.
Free to see. No signup.
More on the people and the money behind Imunon, Inc., from the filings we hold.
Biotechnology raises by companies based in New Jersey, filed within 90 days of this one, largest first.
Get an email when Imunon, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Imunon, Inc. raises, hires or launches. No email unless you switch it on.
Watch Imunon, Inc. →Get the full cited report on Imunon, Inc.
What the filing shows about Imunon, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Imunon, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Imunon, Inc.'s address as 997 Lenox Drive, Suite 100, Lawrenceville, NJ 08648-2311.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Imunon, Inc. is a registered filer with the SEC (CIK 749647) and has filed since 2024-08-16. 2 filings are on record, the latest on 2025-05-28.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Imunon, Inc.'s Form D of 2025-05-28 names Stacy Lindborg, Michael Tardugno, David Gaiero and 7 more as its officers, directors or promoters.
Its new offerings report $13.25M sold across 2 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 766 filings in Biotechnology, totalled by week.
Checked away from the filing. What is below does not come from the record on sec.gov.
The Investor Relations website contains information about IMUNON INC.'s business for stockholders, potential investors, and financial analysts.
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
On the filing as: Executive Officer, Director.
Stacy Lindborg is named as President and Chief Executive Officer on the Form D that Imunon, Inc. filed with the SEC on 28 May 2025, one of 10 people that filing names.
On the filing as: Executive Officer, Director.
Michael Tardugno is named as Executive Chairman on the Form D that Imunon, Inc. filed with the SEC on 28 May 2025, one of 10 people that filing names.
On the filing as: Executive Officer.
David Gaiero is named as Chief Financial Officer on the Form D that Imunon, Inc. filed with the SEC on 28 May 2025, one of 10 people that filing names.
On the filing as: Executive Officer.
Susan Eylward is named as General Counsel and Corporate Secretary on the Form D that Imunon, Inc. filed with the SEC on 28 May 2025, one of 10 people that filing names.
On the filing as: Executive Officer.
Douglas Faller is named as Chief Medical Officer on the Form D that Imunon, Inc. filed with the SEC on 28 May 2025, one of 10 people that filing names.
On the filing as: Executive Officer.
Khursheed Anwer is named as Executive Vice President and Chief Scientific Officer on the Form D that Imunon, Inc. filed with the SEC on 28 May 2025, one of 10 people that filing names.
Donald Braun is named as Director on the Form D that Imunon, Inc. filed with the SEC on 28 May 2025, one of 10 people that filing names.
James Dentzer is named as Director on the Form D that Imunon, Inc. filed with the SEC on 28 May 2025, one of 10 people that filing names.
Frederick Fritz is named as Director on the Form D that Imunon, Inc. filed with the SEC on 28 May 2025, one of 10 people that filing names.
Christine Pellizzari is named as Director on the Form D that Imunon, Inc. filed with the SEC on 28 May 2025, one of 10 people that filing names.
10 people named on the filing — 6 holding an executive role and 4 as directors only.
Named as of the 2025-05-28 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Imunon, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Imunon, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Imunon, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Imunon, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Imunon, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-11-02 (investors.imunon.com).
Each opens in a new tab, filled in for Imunon, Inc.. With no account yet, you sign up free and land on the result.
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/imunon-inc-form-d-25000001